logo
Record Smashing Electron Beam Delivers a Petawatt of Power in an Instant

Record Smashing Electron Beam Delivers a Petawatt of Power in an Instant

Yahoo08-03-2025
Physicists at SLAC National Accelerator Laboratory in the US have shattered the record for most powerful beam of electrons, cramming an ultra-high current of around 100,000 amps into an instant.
At around five times the field strength of what could be achieved previously, the mind-blowing amount of energy in the beam's electric field at SLAC's FACET-II linear accelerator could push the boundaries on experimentation, leading to new discoveries in everything from astrophysics to materials science.
The team's new technique for steering millimeter-long chains of electrons along a magnetic track allows them to squeeze the race down into a photo finish that delivers more than a petawatt of power in one million-billionth of a second.
Particle accelerators have been a vital tool for physicists for nearly a century, using oscillating electromagnetic fields to nudge charged particles up to velocities that come within a whisker of the speed of light.
As the particles change direction their own field shines with high-energy X-ray photons that can illuminate materials for high-resolution imagery.
Place another wall of electromagnetism in front of this beam, the energy from the colliding fields could shake a variety of shiny new particles from the quantum foam itself.
To create more intense flashes or light, or bigger collisions, more energy is needed; either by pushing the particles ever faster, or by ensuring all their energy is delivered in a shorter period of time.
Since the electrons are already traveling at near top velocities as they surf on waves of electromagnetism, more speed isn't possible. By the same reasoning, forcing electrons at the back of the pack to press down on their accelerator and catch up to those in front isn't a solution.
But there is another trick. Though they're all racing at the same speed, the accelerator's electrons are distributed along the slope of an electromagnetic wave as they surf down the tunnel, with some at the 'bottom' and some at the 'top'.
Those at the top have more energy whenever they swerve. To force those at the bottom to slow, the researchers needed a way for them to pump the brakes a touch.
One way commonly used to manage such a situation is the use of a magnetic obstacle that causes lower energy particles to take a slightly longer path, much as a chicane on an actual race track would force a less powerful car to carefully weave left and right while a car with more grunt could push straight through.
By deflecting particles according to their energy level, the chain of electrons could bunch up and – in theory – pack a greater punch.
There's just one problem. Every swerve on the track forces the electrons to shed precious energy in the form of a high-frequency X-ray photon.
To help replace the lost energy, the team inserted into the middle of the chicanes a second magnetic device called an undulator, which pushed the electrons back and forth quickly in another direction. At the same time, a flash of light from a sapphire laser was introduced to control the spread of electrons.
The timely mix of undulations and light shaped the distribution of the chain as it was repeatedly sped up and compressed, replacing a portion of the lost energy while forcing a number of the electrons to overlap within a space barely a third of a micrometer long.
The end result was a powerful lightning in a bottle created with a technique that could be improved upon in future, potentially confining more high-speed electrons to an even smaller space.
This research was published in Physical Review Letters.
Sunken Continents Near Earth's Core Could Unbalance Our Magnetic Field
Earth's Core Could Be Hiding a Vast Reservoir of Primordial Helium
Physicists Create Lab-Grown Diamond Even Harder Than Natural
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vendanta's culls UC microbiome therapy on Phase II fail
Vendanta's culls UC microbiome therapy on Phase II fail

Yahoo

time2 days ago

  • Yahoo

Vendanta's culls UC microbiome therapy on Phase II fail

Vendanta Biosciences will be stopping development of its oral microbiome therapy, VE202, which failed to meet its primary endpoint in a Phase II trial in mild-to-moderate ulcerative colitis (UC). VE202 failed to show improvement in endoscopic response in UC patients in the randomised, double-blind, placebo-controlled COLLECTiVE202 study (NCT05370885), with Vendanta CEO Dr Bernat Olle confirming on LinkedIn that the drug will not be moving forward. In the press release confirming the trial failure, Olle said: 'We are very disappointed that our study did not meet its efficacy endpoints, and our greatest regret is that people living with inflammatory bowel disease will not, for now, have the opportunity to benefit from a new treatment option. 'The gut microbiome is a well-recognised driver of IBD [inflammatory bowel disease], yet remains a facet of the disease untouched by current treatments. As a field, we have not yet succeeded in making a meaningful impact for people with IBD through microbiome-based approaches, but every study moves us closer to that goal.' Vendanta will be sharing further analyses of the UC trial at upcoming scientific meetings. Due to the Phase II failure, Vendanta will be reducing its workforce by 20%, Olle also confirmed in his social media post. Amid the failure, the company said it is now focusing efforts on other pipeline assets, primarily VE303, which is in a Phase III registrational study for the prevention of recurrent C. difficile infection (rCDI). A Phase II trial of the drug demonstrated potentially best-in-disease efficacy with a 30.5% absolute risk reduction and a greater than 80% reduction in the possibility of CDI recurrence. Olle added: 'Our priority at Vedanta remains the successful execution of our ongoing global pivotal study of VE303 for the prevention of recurrent C. difficile infection, with the goal of potentially delivering the first approved live biotherapeutic product in any indication — and, in doing so, addressing a serious health condition with a significant unmet medical need.' The company's other clinical asset, VE707, will be investigated for its ability to prevent infections by multi-drug-resistant organisms that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care. The investigational new drug (IND) submission for VE707 is planned for H1 2026. UC market remains competitive A large number of biologics have also been approved in UC, with the first being Janssen's Remicade (infliximab), which gained US Food and Drug Administration (FDA) approval in 2005. Since then, AbbVie's Humira (adalimumab), Takeda's Entyvio (vedolizumab), and Johnson & Johnson's Stelara (ustekinumab) have also all gained approval in the UC sector. As biosimilars for Humira began to enter the market in 2023, AbbVie is hoping to regain some control in the UC market with Skyrizi (risankizumab-rzaa) after it was approved in June 2024. It recently culled an IL-1 asset as a monotherapy for UC after it failed to show benefit in a Phase II trial. A company that could be set to make its mark in UC is Abivax, with the company's stock surging more than 500% after its first-in-class miRNA regulator, obefazimod, showed an average 16.4% placebo-adjusted clinical remission rate across two Phase III trials. According to GlobalData, the UC market across the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) will reach $10bn in 2031. GlobalData is the parent company of Clinical Trials Arena. "Vendanta's culls UC microbiome therapy on Phase II fail" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time05-08-2025

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on LinkedIn.

Firefighters at higher risk for many cancers, new study finds
Firefighters at higher risk for many cancers, new study finds

UPI

time30-07-2025

  • UPI

Firefighters at higher risk for many cancers, new study finds

A newly published study "supports the growing body of research linking occupation as a firefighter to cancer risk," health researchers say. File Photo (2023) by Bill Greenblatt/UPI | License Photo Firefighters work hard saving lives, and in process put their own lives at heightened risk from skin, kidney and other types of cancers, a new American Cancer Society (ACS) study finds. "Although this isn't favorable news, this study shines a spotlight on the long-term risks firefighters face beyond the immediate dangers of fighting a fire," said lead author Lauren Teras, the ACS' senior scientific director of epidemiology research. "Continued efforts to safeguard the health of firefighters by increasing access to cancer screening, early detection, and prevention are paramount," she added in a news release. The findings were published July 29 in the International Journal of Epidemiology. The study drew on data from the ACS Cancer Prevention Study-II, which tracked rates of cancer deaths over 36 years for people who were cancer-free when the study began in 1982. More than 470,000 people enrolled in the study were firefighters, and their rates of cancer death were compared to male participants working in other fields. Overall, the study "supports the growing body of research linking occupation as a firefighter to cancer risk," conclude Teras and her colleagues. Risks were highest for skin cancers (a 72% rise in risk among firefighters) and kidney cancer (a 39% higher risk). Smaller increases in risk were observed for cancers of the lung (8% higher odds), prostate (14%) and colon (15%), the team reported. According to the researchers, the higher risk for fatal skin cancers might stem from the fact that firefighters are often outside without proper skin protection. Taking better precautions from sun exposure might help protect them, Teras said. The slightly higher risk for lung cancer only arose among firefighters who'd been on the the job for 30 or more years, the researchers pointed out. Teras noted that a prior study from the International Agency for Research on Cancer (IARC) found evidence that firefighting raises the odds for mesothelioma and bladder cancer, but was inconclusive as to other tumor types. "Our findings support the growing body of research linking firefighter exposures to cancer risk," Teras said in an ACS news release. "The associations with skin, kidney, prostate and colorectal cancer notably help to fill gaps for cancers that were considered to have limited or inadequate evidence in the previous IARC review." More information There's more on preventing skin cancer at the Skin Cancer Foundation. SOURCES: American Cancer Society, news release, July 28, 2025; International Journal of Epidemiology, July 29, 2025 Copyright © 2025 HealthDay. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store